Recurrent myocardial infarction associated with gefitinib therapy

Journal of Thrombosis and Thrombolysis

Volumn 32, Issue 1, 2011, Pages 120-124

  Lynch Jr , Donald R ^a   Kickler, Thomas S ^a   Rade, Jeffrey J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gefitinib; Myocardial i.nfarction.; Plaque rupture; Platelets; Thromboxane

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; EVEROLIMUS; GEFITINIB; HEPARIN; IBUPROFEN; OCTREOTIDE; PANTOPRAZOLE; PRAVASTATIN; THROMBOXANE A2;

ADULT; ANGIOCARDIOGRAPHY; APPENDIX CANCER; ARTICLE; CANCER CHEMOTHERAPY; CARCINOID; CASE REPORT; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; HEART INFARCTION; HUMAN; ILEOCECAL VALVE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LONG TERM CARE; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NIGHT SWEAT; PAIN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTAGLANDIN URINE LEVEL; RECURRENT DISEASE; RECURRENT INFECTION; SMALL INTESTINE CANCER; THROMBOCYTE ACTIVATION;

ANTINEOPLASTIC AGENTS; CARCINOID TUMOR; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOPLASM METASTASIS; QUINAZOLINES;

EID: 80052459392     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-010-0539-4     Document Type: Article

References (17)

1. Lurje G, Lenz HJ (2009) EGFR signaling and drug discovery. Oncology 77:400-410
2. Reck M (2009) Gefitinib in the treatment of advanced non-smallcell lung cancer. Expert Rev Anticancer Ther 9:401-412
3. AstraZeneca Pharmaceuticals. Iressa summary of product characteristics. http://www.iressa.com/-mshost5259502/content/6906430/Gefitinib-PI
4. Kanazawa S, Yamaguchi K, Kinoshita Y, Muramatsu M, Komiyama Y, Nomura S (2006) Aspirin reduces adverse effects of gefitinib. Anticancer Drugs 17:423-427 (Pubitemid 44309985)
5. Chen MH, Kerkela R, Force T (2008) Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 118:84-95
6. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239-245 (Pubitemid 12149145)
7. Yamaguchi K, Kanazawa S, Kinoshita Y, Muramatsu M, Nomura S (2005) Acute myocardial infarction with lung cancer during treatment with gefitinib: the possibility of gefitinib-induced thrombosis. Pathophysiol Haemost Thromb 34:48-50 (Pubitemid 41642805)
8. Kanazawa S, Yamaguchi K, Kinoshita Y, Muramatsu M, Komiyama Y, Nomura S (2005) Gefitinib affects functions of platelets and blood vessels via changes in prostanoids balance. Clin Appl Thromb Hemost 11:429-434 (Pubitemid 41546769)
9. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919-933
10. Pulcinelli FM, Riondino S, Celestini A, Pignatelli P, Trifiro E, Di Renzo L, Violi F (2005) Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J Thromb Haemost 3:2784-2789 (Pubitemid 41819808)
11. Armstrong PC, Truss NJ, Ali FY, Dhanji AA, Vojnovic I, Zain ZN, Bishop-Bailey D, Paul-Clark MJ, Tucker AT, Mitchell JA, Warner TD (2008) Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. J Thromb Haemost 6:1933-1943
12. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, Johnston SC, Steinhubl SR, Mak KH, Easton JD, Hamm C, Hu T, Fox KAA, Topol EJ (2008) Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid. determinants and effect on cardiovascular risk. Circulation 118:1690
13. Gluckman TJ, McLean RC, Schulman SP, Kickler TS, Shapiro EP, Conte JV, et al. (2011) Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. J Am Coll Cardiol. (in press)
14. Miyagawa J, Higashiyama S, Kawata S, Inui Y, Tamura S, Yamamoto K, Nishida M, Nakamura T, Yamashita S, Matsuzawa Y (1995) Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques. J Clin Invest 95:404-411
15. Dahal BK, Cornitescu T, Tretyn A, Pullamsetti SS, Kosanovic D, Dumitrascu R, Ghofrani HA, Weissmann N, Voswinckel R, Banat GA, Seeger W, Grimminger F, Schermuly RT (2010) Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med 181:158-167
16. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R (2010) Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 30:1282-1292
17. Ben Dor I, Kleiman NS, Lev E (2009) Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J Cardiol 104:227-233